Hong KongJune 3, 2026 /PRNewswire/ — Mr. Zhang Jinwei of Dandelion has joined HKBMIA (Hong Kong Biomedical Innovation Association) as a Director!
Founder of Dandelion, Founding Dean of Shanghai Lingang Industrial University’s Biomedical College, Zhang Jinwei
Mr. Zhang Jinwei
Lifetime Fellow of the Royal Society of Arts (RSA)
Founder of Dandelion, Founding Dean of Shanghai Lingang Industrial University’s Biomedical College
Ph.D. Candidate in Pharmaceutical Engineering, Senior Engineer
Angel Investor in Biomedical Ventures;
Member of the First Pharmaceutical Regulatory Science Professional Committee of Shanghai Pharmaceutical Association;
Legal Representative of Shenzhen Biomedical Industry Alliance;
Off-Campus Master’s Supervisor at Tianjin University of Science and Technology;
Chief Representative of the International Pharmaceutical Project Management Association (IPPM) in China;
Visiting Professor at the Canadian Academy of Pharmaceutical Engineering, Strategic Advisor to a Listed Pharmaceutical Group;
Founder of the Biomedical Localization Promotion Federation (BLA);
Developer of the PPMP (Pharmaceutical Project Management Professional) Level C International Certification Course;
With over 20 years of deep experience in the pharmaceutical industry, he has participated in and led major projects under the “Eleventh Five-Year Plan,” served as a senior executive and strategic advisor for a well-known listed pharmaceutical group, and is well-versed in the entire pharmaceutical industry chain. He has provided consulting services and training to government bodies, associations, industrial parks, regulatory authorities, and over 100 pharmaceutical companies. He serves as a think tank expert and advisor for multiple government departments and biomedical industrial parks. He has invested in and incubated nearly 20 biomedical projects. He has authored and published professional books through China Medical Science and Technology Press, including the “English-Chinese Bilingual Dictionary of Global Pharmaceutical Terminology,” the “FDA Warning Letter Review and Case Interpretation” series, the “White Paper on Top-Level Design and Implementation Path of Intelligent Manufacturing in Biomedicine,” the “Bilingual Dictionary of Biopharmaceuticals,” and “The Past and Present of Vaccines.”
Some cases of Dandelion Venture Capital and Incubation:
1. Shenzhen Xianggen Biotechnology (Antifungal innovative drugs and cyclic peptide innovative drugs)
2. Shenzhen Liying Biotechnology (Synthetic biology, triple-helix collagen recombinant protein)
3. Shenzhen Jiayu Biotechnology (Cell therapy targeting solid tumors)
4. Shenzhen Ningju Biotechnology (Transformation of high-performance biological base materials)
5. Shenzhen Shanjizhixin (Early screening instrument IVD for Alzheimer’s disease)
6. Shanghai Kaixi Life (CDMO in the life sciences field)
7. Shanghai Yingnuomabo (AI + proteomics big data)
8. Wenzhou Weiqiong Microbiology (Domestic substitution, quantitative strains, biological indicators, etc.)
9. Suzhou Yilit Technology (Life science instruments, domestic liquid chromatography, breaking foreign monopolies)
10. Tianjin Chuanpu Biotechnology (Industrialization of pre-prepared culture media)
11. Wuhan Vitzhilian (High-precision clone picking precision instruments)
12. Wuhan Xindong Biotechnology (Pet cat CRO and pet drug development)
13. Suzhou Baojuhe Medical (Automatic injection pens)
14. Bainuokang Regenerative Medicine (Exosome-based aesthetic products)
15. Feiya Biotechnology (Pet oral treatment drugs)
16. Medicovestor (ADC drugs for treating pancreatic cancer)
17. Kelaisuo Medical (Exosome-based innovative drugs for treating bone and joint diseases)
Project Management Cases (Consulting/Training):
Livzon Group, Tasly, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Shineway Pharmaceutical, Fosun Kite, Zhaowei Aoli Pharmaceutical, Kunming Pharmaceutical Group, Tongrentang, China Resources Double-Crane, Jianmin Pharmaceutical, Simcere Pharmaceutical, Luye Pharma, China Resources Pharmaceutical, Kexing Pharmaceutical, BeiGene, Sansheng Biotechnology, Chuangmai Biotechnology, Zhidao Biotechnology, Lishan Biotechnology, Kanglitai Pharmaceutical, Jemincare Group, Salubris Pharmaceutical, Dongcheng Pharmaceutical, North China Pharmaceutical Jintan Biotechnology, Keruide Pharmaceutical, Huanghai Pharmaceutical, Baiyao Pharmaceutical, Wujing Pharmaceutical, Li Shizhen Pharmaceutical Group, Huibaoyuan Pharmaceutical, Harbin Sanlian Pharmaceutical, Wantong Pharmaceutical, Huanghai Pharmaceutical, Boda Pharmaceutical, Yuanda Feiyun Pharmaceutical, Kanghong Pharmaceutical, Fuyuan Pharmaceutical, etc.
Biomedical Industrial Park Cases (Consulting/Training):
Shenzhen Baolong Biomedical Industrial Park, Shijiazhuang Biomedical Industrial Park, China Pharmaceutical Harbor, Shanghai Lingang Biomedical Industrial Park, etc.
Regulatory Authority Cases (Training):
Hebei Provincial Drug Administration, Jilin Provincial Drug Administration, Hainan Provincial Drug Administration, Fujian Provincial Drug Administration, Hubei Provincial Drug Administration, Sichuan Provincial Drug Administration, Zhejiang (Quzhou, Shaoxing) Drug Administration, Liaoning Provincial Drug Administration, etc., providing GMP inspector training sessions.